Daewoong Pharmaceutical and Inventage Lab, a startup specializing in drug supply system (DDS) platform, have agreed to develop male baldness remedy, IVL3001 and IVL3002.
IVL3001 and IVL3002 are long-term hair-loss options to be developed from Daewoong’s pipeline and shall be administered as soon as each month or three months. Inventage Lab’s DDS know-how, Involucrin (IVL)-Precision Particle Fabrication Microsphere, is supplied with male hair loss remedy.
Finasteride, the ingredient of IVL3001 and IVL3002, is among the verified supplies accepted by the U.S. Meals and Drug Administration. It has confirmed its efficacy and security in stopping hair loss and has been broadly used.
IVL3001, a month-long performing drug for male hair loss, is scheduled to be launched in 2024 with a part 1 scientific trial deliberate in early 2021. IVL3002, a 3 month-acting hair loss remedy, is present process non-clinical trials.
“Daewoong Pharmaceutical has numerous pipelines, together with anticancer medication, central nervous system, and weight problems, based mostly on 20 years of manufacturing and analysis expertise in long-acting injection,” Daewoong Pharmaceutical CEO Jeon Seng-ho mentioned. “We’re planning to hurry up the event of long-acting male hair loss therapies to enter the worldwide market.”
Inventage Lab Kim Ju-hee mentioned, “It’s a very useful alternative to mix our revolutionary platform tech with Daewoong Pharmaceutical, which possesses growth experience and gross sales community,”